
ATTORNEY'S DOCKET NUMBER DI17 Rec'd PCT/PTO FORM PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (MODIFIED) X-14075 U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) 10/509770 **CONCERNING A FILING UNDER 35 U.S.C. 371** PRIORITY DATE CLAIMED INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING PCT/US/03/08455 DATE 27 March 2003 (27.03.2003) 29 March 2002 (29.03.2002) TITLE OF INVENTION: PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS APPLICANT(S) FOR DO/EO/US: Michael Philip Cohen, Daniel Timothy Kohlman, Sidney Xi Liang, Vincent Mancuso, Frantz Victor, Yao-Chang Xu, Bai-Ping Ying, DeAnna Piatt Zacherl, and Deyi Zhang Applicant herewith submits to the U.S. Designated/Elected Office (DO/EO/US) the following items and other information: 1. This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. b. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) are transmitted herewith (required only if not transmitted by the International Bureau). a. b. have been transmitted by the International Bureau. c. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. 8. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. \mathbf{X} An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). X 10. A declaration of the inventors 35 U.S.C. 371(c)(4) was provided in the PCT Request Form. 11. X A copy of the International Preliminary Examination Report (IPER), including any annexes, and, if not in English, an English language translation of the annexes to the IPER under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 12. to 18. below concern document(s) or information included: 12. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 13. X An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 14. Assignment has been recorded at reel , frame 15. X A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. A Sequence Listing, 1.821 Statement, and diskette. 17. A change of power of attorney and attachments. 18. Other items or information: Please amend the first page of the specification by inserting the following cross-reference after the title: "This is the national phase application, under 35 USC 371, for PCT/US03/08455, filed 27 March 2003, which, claims the

benefit, under 35 USC 119(e), of US provisional application 60/369,088, filed 29 March 2002."

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.5) INTERNATIONAL APPLICATION NO. ATTORNEY'S DOCKET NUMBER							
10/509770 PCT/US03/08455					X-14075		
19. X The following	g fees are submitted:			CA	LCULATIONS	PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1080.00							
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$920.00							
		fee (37 CFR 1.482) not pa (a)(2)) paid to USPTO					
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$730.00							
International preliminary examination fee paid to USPTO (37 CRF 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)\$100.00							
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$	920.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than2030 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	22000		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	+			
Total claims	67-20=		X \$18.00	\$	846.00		
Independent claims	9-3=	6	X \$86.00		516.00	-	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$290.00				1 -	290.00		
TOTAL OF ABOVE CALCULATIONS =				<u> </u>	,652.00		
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity				\$,002.00		
Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).							
SUBTOTAL =					,572.00		
Processing fee of \$130.00 for furnishing English translation later than 2030 months from the earliest claimed priority date (37 CFR 1.492(f)). +							
TOTAL NATIONAL FEE =					,572.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31).							
\$40.00 per property							
TOTAL FEES ENCLOSED =					,572.00		
,			***		Amount to be	\$	
					refunded		
-					charged	\$	
b. X Please charg	ne amount of \$ e my Deposit Accoun sheet is enclosed.	to cover the above fe t No. 05-0840 in the amount		cove	r the above fees. A	A duplicate	
c. X The Commis	sioner is hereby author	orized to charge any addit No. 05-0840. A duplicate				any	
NOTE: Where an ap (37 CFR 1.13	propriate time limit 37(a) or (b)) must be	under 37 CFR 1.494 or filed and granted to res	1.495 has not been	n met	, a petition to rev	ive	
	LLY AND COMPANY						
PATENT DIVISION SIGNATURE							
P.O. BOX 6288 INDIANAPOLIS, INDIANA 46206-6288							
R. Craig Tucker				25885			
Date (317) 433-9829				PATENT TRADEMAR	RK OFFICE		
45,165	OED.	TELEPHONE NUM	BER				



CERTIFICATE UNDER 37 CFR 3.73(b)

	DT04 Rec'd PCT/PT0 2 8 SEP 20
Applicant:	Michael Philip Cohen, et al.
Application 1	No.: US Nat'l Phase of PCT/US03/08455 Filed: 27 March 2003
Entitled: <u>PY</u>	RIDINOYLPIPERIDINES AS 5-HT1F AGONISTS
ELI LILLY A	, a <u>CORPORATION</u> (Type of Assignee, e.g. corporation, partnership, university, government agency, etc.)
	s the assignee of the entire right, title and interest in the patent application identified above by virtue of either:
A. [X] An ass	ignment from the inventor(s) of the patent application identified above.
[] The [X] Th	e assignment was recorded in the Patent and Trademark Office at Reel, Frame. le assignment is being submitted separately for recordation; a copy of this assignment is attached.
	OR
B. [] A chain	of title from the inventor(s), of the patent application identified above, to the current assignee as shown below:
1.	From: To: The document was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
2.	From: To: The document was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
3.	From: To: To: The document was recorded in the Patent and Trademark Office at Reel, Frame, or for which a copy thereof is attached.
[]	Additional documents in the chain of title are listed on a supplemental sheet.
[X] Copies of a	ssignments or other documents in the chain of title are attached.
The undersigne	d (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee.
belief are believ like so made, ar	that all statements made herein of my own knowledge are true, and that all statements made on information and red to be true; and further, that these statements are made with the knowledge that willful false statements, and the e punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that he statements may jeopardize the validity of the application or any patent issuing thereon.
Enton	ber 28,2004 m with
Date	R. Craig Tucket Patent Attorney

Applicant(s): Michael Philip Cohen, Daniel Timothy Kohlman, Sidney Xi Liang, Vincent Mancuso, Frantz Victor, Yao-Chang

Xu, Bai-Ping Ying, DeAnna Piatt Zacherl, and Deyi Zhang International Application No.: PCT/US03/08455

Filed: 27 March 2003 (27.03.2003)

Invention: PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS

Lilly Reference:

X-14075

Earliest Priority Date: 29 March 2002 (29.03.2002)

Certificate Under 37 C.F.R. § 1.10

Attention: DO/EO
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

"Express Mail" mailing label number: EL 832896926 US

Date of Deposit: 9-28-04

I hereby certify that the following attached paper or fee

Transmittal Letter to the United States Designated/Elected Office (US) concerning a filing under 35 U.S.C. 371 of the International Application identified above is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

(Typed or printed name of person mailing paper)

(Signature of person mailing paper or fee